The Role of PD-1 in Chronic Lymphocytic Leukemia
April 14, 2025
CLL cells express PD-1 when actively growing, and increased PD-1 expression may be an early sign of resistance to BTK inhibitor therapy.
CLL cells express PD-1 when actively growing, and increased PD-1 expression may be an early sign of resistance to BTK inhibitor therapy.
During a 30-minute phone call, individuals have the opportunity to ask questions and get honest input from a fellow patient who has been through it before.
There’s a 21 percent chance of chronic lymphocytic leukemia (CLL) patients getting a second COVID-19 infection within a year of the first infection.
Patients with chronic lymphocytic leukemia (CLL) have an impaired immune system, which leads to a reduced ability to fight infections and other diseases.
Chronic lymphocytic leukemia (CLL) patients with abnormal bone health are at high risk for fragility fractures, which can occur with minimal trauma.
Though chronic lymphocytic leukemia (CLL) is rare in younger patients, adolescents and young adults with CLL have a better prognosis than older patients.
CLL Society has created our Statement on Mask Wearing and Other Protective Measures for Those Living with CLL to protect against respiratory infections spread.
Chronic lymphocytic leukemia (CLL) is a slow-growing blood cancer involving the abnormal overgrowth of a type of white blood cell called B-lymphocytes.
A newly published paper in Clinical Cancer Research found that when patients successfully treated with fixed-duration ibrutinib-venetoclax developed progressive disease, they had no acquired resistance mutations in BTK, BCL2, or PLCG2.